Business Description
Indaptus Therapeutics is a New York-based clinical-stage company focused on developing treatments that use the immune system to fight cancer and viral infections. Its primary drug candidate, Decoy20, is being studied as both a standalone therapy and in combination with other treatments for several serious conditions, including multiple cancer types such as lymphoma, colorectal, liver, and pancreatic tumors, as well as chronic hepatitis B and HIV. The company was previously called Intec Parent Inc. before adopting its current name in August 2021.
